In the first quarter, total U.S. sales of Eylea and Eylea HD dropped by 26% year over year to $1.04 billion, but revenue from the latter increased by 54% year over year to $307 million. Eylea HD ...

Regeneron is facing biosimilar competition for Eylea, one of its biggest growth drivers. In the first quarter, the company's revenue decreased by 4% year over year to $3 billion.

On May 20, Regeneron Pharmaceuticals — a U.S.-based biotechnology company best known for drugs like Dupixent and Eylea — was approved as the lead bidder to acquire substantially all of 23andMe ...

Even though a setback in a clinical trial and declining Eylea sales may logically lead to a compression in valuation multiples, we believe the selling pressure on REGN stock at values below $500 ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Novartis ups the ante in the wet AMD market battle with Bayer/Regeneron’s Eylea, launching a trial that will test 16-week dosing for its new antibody brolucizumab.

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

U.S. sales of Eylea HD increased by 54% year over year to $307 million in the period. This version of Eylea should continue to steal some patients away from the old formulation due to the former's ...

Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 43 unusual trades. Delving ...

4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.

On Friday, RBC Capital Markets downgraded Regeneron (NASDAQ: REGN) Pharmaceuticals’ shares, moving the rating from Outperform to Sector Perform.The firm also significantly reduced the price ...